Cello Health PLC

Cello Health on track and buoyed by strength of pharma consultancy

The health division saw good like-for-like gross profit growth and better operating margins

Work for big pharma has increased

Cello Health plc (LON:CLL) expects to hit expectations for 2018 after an “excellent year” at its big pharma consultancy division.

Strong like-for-like growth in this arm, known as health, offset a slower outcome from brand and marketing operation Signal.

WATCH: Cello Health Plc expects to hit expectations for 2018 after 'excellent year'

The health division also saw good like-for-like gross profit growth and better-operating margins.

Operating profit performance was good in all three core capabilities consulting, insight and communications, said the statement.

"Contributions from the businesses acquired in 2017 continue to be in line with the board's expectations, extending the reach of Cello Health into the biotech community to complement the pharmaceutical core of the business and increasing the focus on the US market."

Signal’s slower year reflected lower activity by some UK-based clients.

Full year results will include £1.2mln of start-up costs for the launch of social media analytics tool Pulsar in the US and the new Boston office of Cello Health. Restructuring Signal’s capacity in Cheltenham has also cost £300,000.

Pulsar US will be consolidated into the group’s results in 2019.


Quick facts: Cello Health PLC

Price: £1.27

Market: AIM
Market Cap: £134.73 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cello Health PLC named herein, including the promotion by the Company of Cello Health PLC in any Content on the Site, the Company receives from...



Full interview: Cello Health reports good growth in profits and strong cash flow

Cello Health PLC's (LON:CLL) Mark Scott tells Proactive London they've seen good growth in profits and strong cash flow for the first half of the year said that he's confident about the rest of the year too. The group delivered net revenue of £54.5mln for the first six months of the year,...

2 days, 15 hours ago

2 min read